Regulatory approval

Published by the Health Service Executive. Approved

Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA 1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube cancer, and primary peritoneal carcinoma who are in response (complete or partial) following completion of first-line platinum based chemotherapy

This is written in the approval document.

Reimbursement

CDS

Citation

Olaparib (Tablet) Monotherapy, 2025, version number 5b, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) BRCA1 oncogenic variants Ovarian Epithelial Tumor Olaparib
HSE (1) BRCA1 pathogenic variants Ovarian Epithelial Tumor Olaparib
HSE (1) BRCA2 oncogenic variants Ovarian Epithelial Tumor Olaparib
HSE (1) BRCA2 pathogenic variants Ovarian Epithelial Tumor Olaparib
HSE (1) BRCA1 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
HSE (1) BRCA1 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
HSE (1) BRCA2 oncogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
HSE (1) BRCA2 pathogenic variants High-Grade Serous Fallopian Tube Cancer Olaparib
HSE (1) BRCA1 oncogenic variants Peritoneal Serous Carcinoma Olaparib
HSE (1) BRCA1 pathogenic variants Peritoneal Serous Carcinoma Olaparib
HSE (1) BRCA2 oncogenic variants Peritoneal Serous Carcinoma Olaparib
HSE (1) BRCA2 pathogenic variants Peritoneal Serous Carcinoma Olaparib